
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is in a strong position with its diverse portfolio of regenerative medicine products, including Apligraf and Dermagraft, which have demonstrated the ability to drive more rapid and significant healing in chronic wounds. Despite challenges in the current reimbursement landscape, the company is well positioned to grow in both the advanced wound care and surgical & sports medicine markets, with a potential market opportunity of $31 million for its product ReNu alone. Management has a clear focus on metrics that drive value creation, and the company's strong balance sheet and expected growth in margins make it a compelling investment opportunity for the long term.
Bears say
Organogenesis Holdings is facing multiple headwinds that could negatively impact its financial performance in the near future. These include the recent CMS reimbursement changes, which has led to a significant contraction in the company's end market, and the potential for further disruptions as smaller players exit the market. Additionally, the company's portfolio of regenerative medicine products may face challenges in gaining traction and utilization due to uncertainty around coding, coverage, and commercialization. These factors are likely to result in lower revenue and profitability for Organogenesis Holdings in the short term, with potential upside only expected from its ReNu product, which still faces regulatory and adoption challenges.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares